All In Biotech

NDA 217472 · Fresenius Kabi USA

Rocuronium Bromide

Rocuronium Bromide · Intravenous

Last checked: Nov 19, 2026Latest source record: Jul 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Jun 9, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

544

61 Phase 3, 36 recruiting

FAERS reports

12,125

11,055 serious, 968 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 2, 2026.

Rocuronium Bromide Injection is indicated as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Rocuronium Bromide Injection is a nondepolarizing neuromuscular blocking agent indicated as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. ( 1 )

Mechanism: Rocuronium Bromide Injection is a nondepolarizing neuromuscular blocking agent with a rapid to intermediate onset depending on dose and intermediate duration. It acts by competing for cholinergic receptors at the motor end-plate. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine and edrophonium.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 9, 2025 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
2 products under this application
  • ROCURONIUM BROMIDE · ROCURONIUM BROMIDE 50MG/5ML (10MG/ML) · SOLUTION, INTRAVENOUS · Prescription
  • ROCURONIUM BROMIDE · ROCURONIUM BROMIDE 100MG/10ML (10MG/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Rocuronium" as an intervention, any sponsor and status, largest first.

All 544 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • anaphylactic reaction1,326
  • hypotension1,158
  • drug ineffective1,155
  • anaphylactic shock1,073
  • cardiac arrest685
  • drug interaction476
  • tachycardia435
  • off label use428
  • bradycardia404
  • bronchospasm385
  • rash297
  • urticaria287

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200444
200586
200658
200759
2008108
2009180
2010227
2011302
2012332
2013263
2014321
2015322
2016607
2017491
2018699
2019853
2020928
2021873
2022895
2023985
20241,005
20251,137
20261,348

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • Current · updated Nov 18, 2026

    Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-442-05). Check wholesalers for inventory

  • Current · updated Nov 18, 2026

    Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-444-10). Check wholesalers for inventory

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,129 on PubMed

Sponsor: Fresenius Kabi USA

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.